Advertisement

Picture Berlin Partner Top News Tacalyx Extends Seed Round to €14m 650x100px
Document › Details

BioCopy AG. (4/9/24). "Press Release: BioCopy Expands Corporate Portfolio with Acquisition of Perspix Biotech GmbH". Basel.

Organisations Organisation BioCopy AG (CH)
  Group BioCopy (Group)
  Organisation 2 Perspix Biotech GmbH
  Today BioCopy Analytix GmbH
  Group BioCopy (Group)
Products Product roPROTix platform (automated RnD end-to-end solution for biotherapeutics)
  Product 2 drug discovery technology
Index term Index term Perspix Biotech–BioCopy: investment, 20403 acquisition of Perspix Biotech GmbH by BioCopy AG + renamed to BioCopy Analytix GmbH
Persons Person Wiedenfels, Matthias (BioCopy 2023Q4– CEO formerly CEO of Stada Arzneimittel AG)
  Person 2 Duppé, Claudia (BioCopy 202310 Strategic Marketing + Comunications)
     


> The acquisition radically accelerates the discovery and development of next generation biological drug candidates through Perspix' end-to-end automated development platform roPROTix

> The acquisition puts BioCopy at the forefront of AI-powered engineering of complex biotherapeutics


BioCopy AG, a research-based biotechnology company headquartered in Basel, Switzerland, today announced the acquisition of Perspix Biotech GmbH. Founded in 2021 and based in Frankfurt am Main, Germany, Perspix Biotech with its end-to-end automated platform roPROTix combines artificial intelligence and robotics for the discovery and development of next-generation multi-specific biotherapeutics. As part of BioCopy AG, Perspix Biotech GmbH will be renamed as BioCopy Analytix GmbH and provide analytical and other services to the company group.

“Integrating Perspix Biotech’s technology into our existing drug discovery ecosystem is a key strategic milestone for our business”, said Dr. Matthias Wiedenfels, CEO of BioCopy. “With BioCopy’s expertise in precision screening of cancer targets for the development of novel complex biotherapeutics, and the newly acquired know-how in end-to-end automated optimization and development of such drug candidates, we now tightly intertwine both technologies into one truly innovative AI-powered and experimental data-driven, automated development platform – which sets BioCopy apart.”

The acquisition is Wiedenfels’ first transformative act in his position as BioCopy’s CEO which he took over in late 2023. He has an outstanding history as top manager with over 20 years of experience in the pharmaceutical industry, especially in his former role as CEO of the international pharmaceutical company STADA Arzneimittel AG, in which he achieved impressive increases in value for the company, its shareholders and patients.

“The current joined efforts put our company at the forefront of AI-powered engineering of complex, multi-specific biotherapeutics. BioCopy is able to accelerate the development time from a decade long marathon to a fast sprint. Our drug candidates carry minimal risks and promise pharmaceutical companies a maximum success rate”, commented Dr. Jörg Birkenfeld, CSO at BioCopy since early 2024. Birkenfeld is the mastermind behind the automated lab. He has extensive experience in biotherapeutics development, particularly in engineering therapeutic antibodies, and held leading research positions at renowned pharmaceutical companies such as Bayer and Sanofi.

“Our first move is to take significantly faster paths in the search for new cancer drugs. Our longer-term goal is to expand our endeavors beyond cancer by developing next generation biotherapeutics also against immunological and neurological disorders”, said Wiedenfels.


About BioCopy

BioCopy is a multinational company headquartered in Switzerland with a state-of-the-art research and development facility in Germany. We focus on biotherapeutic drug discovery and development using our end-to-end automated, AI-powered platform. We are convinced that cancer can be cured with ingenuity and AI, aided by the extraordinary power of our body’s own immune system. With our unique platform we are working continuously to develop next generation biotherapeutic drug candidates with unprecedented power and safety fast, which will transform today’s pharmaceutical industries. With that we positively impact patients' lives while creating value for society and the company's shareholders.


Forward-looking statements

This press release contains forward-looking statements. These statements may be identified by words such as "anticipate", "believe", "estimate", "expect", "forecast", "potential" and similar words and phrases. Forward-looking statements should not be relied upon. Such statements are always subject to risks and uncertainties that could cause actual results to differ from the expectations expressed. The statements are based on current assumptions and expectations and speak only as of the date of this press release. BioCopy undertakes no obligation to publicly update any forward-looking statements contained in this press release.


Contact

Dr. Claudia Duppé
Strategic Marketing and Communications
public.relations@biocopy.com

   
Record changed: 2024-05-08

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for BioCopy (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px




» top